The drug DDC is one of the few hopes on the dark horizon of an AIDS patient. Recent studies, including one reported at last month's International Conference on AIDS in Florence, have shown that DDC, formally known as dideoxycytidine, can reduce the activity of the AIDS virus, especially in combination with the medication AZT. Although Hoffman-La Roche has made the drug available to 4,000 participants in a research program, many people remain ineligible because they are on other anti-AIDS drugs or do not yet have symptoms of the disease. But the major obstacle is that the drug has yet to be...
To continue reading:
or
Log-In
